Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Lycosa Tarantula
Brand Name
Tarentula Hispana
Generic Name
Lycosa Tarantula
Active Ingredient
Lycosa TarantulaCategory
Standardized Insect Venom Allergenic Extract [EPC]
Variants
6
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Tarentula Hispana, you must consult a qualified healthcare professional.
| 30 [hp_C]/30[hp_C] | PELLET | ORAL | 0220-4930 |
| 1 [hp_M]/[hp_M] | PELLET | ORAL | 0220-4935 |
| 6 [hp_C]/1 | PELLET | ORAL | 0220-4941 |
Detailed information about Tarentula Hispana
Lycosa Tarantula is a standardized biological extract primarily utilized as an allergenic agent for immunotherapy and in specific homeopathic preparations. It belongs to the class of Standardized Insect Venom Allergenic Extracts and is monitored for its complex immunological effects.
Dosage for Lycosa Tarantula must be highly individualized, particularly when used for immunotherapy. There is no 'one-size-fits-all' dose.
Lycosa Tarantula extracts are used in pediatric populations for venom immunotherapy, provided the child has a history of systemic reactions.
No specific dose adjustments are typically required for renal impairment because the proteins are metabolized by proteases rather than cleared solely by the kidneys. However, patients with renal failure may have altered immune responses.
No adjustments are necessary for hepatic impairment, as the liver's CYP450 system is not the primary route of metabolism for this biological product.
Elderly patients require cautious dosing. The primary concern is the patient's ability to tolerate a systemic reaction or the administration of epinephrine if an emergency occurs. Cardiovascular stability should be assessed before starting therapy.
In immunotherapy, a missed dose can be dangerous because the patient's tolerance may decrease.
An overdose of Lycosa Tarantula extract typically manifests as a severe systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without direct medical guidance, as this increases the risk of life-threatening reactions.
Most patients receiving Lycosa Tarantula extracts for immunotherapy will experience local reactions. These are generally not dangerous but can be uncomfortable.
Lycosa Tarantula is a potent biological agent. Its use is restricted to specific clinical scenarios where the benefit of desensitization or diagnostic clarity outweighs the inherent risks of venom exposure. Patients must be fully informed of the signs of a systemic reaction before beginning therapy.
No specific FDA black box warning exists solely for Lycosa Tarantula, but it falls under the class-wide warnings for allergenic extracts. These warnings emphasize that the product can cause severe, life-threatening systemic reactions, including anaphylaxis. Treatment must be supervised by a physician, and patients must be observed for at least 30 minutes post-injection.
Lycosa Tarantula must NEVER be used in the following circumstances:
Lycosa Tarantula is generally classified as FDA Pregnancy Category C. This means there are no adequate, well-controlled studies in humans.
It is unknown whether the protein components of Lycosa Tarantula are excreted in human milk. However, since these are large proteins that are digested in the infant's stomach if ingested, the risk to a nursing infant is considered extremely low. The primary concern remains the mother's stability and the potential need for emergency medications like epinephrine, which can temporarily affect milk supply.
Lycosa Tarantula acts through two distinct pathways depending on the concentration and preparation. In Immunotherapy, it acts as an immunomodulator. It induces the production of IL-10 and TGF-beta by T-regulatory cells, which suppresses the IgE-mediated mast cell response. This leads to a significant increase in venom-specific IgG4 antibodies, which act as 'neutralizing' antibodies.
In its Pharmacological/Toxicological profile, the venom contains peptides that act as Cholinergic Muscarinic Antagonists and Adrenergic Agonists. These peptides bind to G-protein coupled receptors (GPCRs) and ion channels. For example, some lycotoxins are known to inhibit the reuptake of norepinephrine, effectively acting as an adrenergic agonist by increasing the concentration of the neurotransmitter in the synapse.
Common questions about Tarentula Hispana
Lycosa Tarantula is primarily used as an allergenic extract for venom immunotherapy (VIT) in patients who have a history of severe allergic reactions to spider bites. By administering gradually increasing doses of the extract, healthcare providers can desensitize a patient's immune system, reducing the risk of life-threatening anaphylaxis from future bites. Additionally, it is used in diagnostic skin testing to confirm specific venom allergies. In the field of homeopathy, highly diluted forms of the extract are used to treat conditions involving extreme restlessness, nervous agitation, and certain types of nerve pain. It is important to note that these uses are distinct and require different preparations and medical oversight.
The most common side effects associated with Lycosa Tarantula injections are local reactions at the site of administration. These typically include redness, swelling, itching, and a small raised bump or wheal that appears shortly after the shot. These reactions are usually mild and resolve within 24 to 48 hours without specific treatment. Some patients may also experience a general sense of fatigue or a mild headache following their appointment. In homeopathic use, some individuals report a 'homeopathic aggravation,' which is a temporary, slight increase in their original symptoms before improvement occurs. Any reaction that spreads beyond the injection site should be reported to a doctor immediately.
It is generally advised to avoid alcohol consumption on the day of a Lycosa Tarantula injection. Alcohol acts as a vasodilator, meaning it widens the blood vessels, which can increase the speed at which the venom proteins are absorbed into the bloodstream. This rapid absorption can increase the risk of a systemic allergic reaction or make a reaction more severe if one occurs. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as dizziness or flushing, making it harder for the patient or medical staff to intervene early. For these reasons, patients should wait at least 24 hours after an injection before consuming alcohol.
The safety of Lycosa Tarantula during pregnancy is a complex issue that requires a detailed discussion with an allergist. It is classified as Pregnancy Category C, meaning there is insufficient human data to rule out risks. Generally, doctors will not start a new course of immunotherapy during pregnancy because of the risk that a severe allergic reaction (anaphylaxis) could deprive the fetus of oxygen. However, if a woman is already on a stable maintenance dose and is tolerating it well, the therapy is often continued to prevent a reaction to a natural spider bite. Each case is evaluated individually based on the mother's risk of exposure and her history of reactions.
Lycosa Tarantula immunotherapy is not an immediate treatment; it is a long-term process that requires patience. The 'build-up phase,' where doses are gradually increased, typically lasts 3 to 6 months. Most patients do not achieve significant clinical protection against spider bites until they have reached their maintenance dose, which usually occurs around the 6-month mark. For the best long-term results and a potential permanent reduction in allergy severity, a full course of treatment usually lasts between 3 and 5 years. Homeopathic effects may be noticed sooner, often within a few days or weeks, depending on the condition being treated.
While you can stop taking Lycosa Tarantula at any time without experiencing physical withdrawal symptoms like those seen with opioids or antidepressants, doing so has clinical consequences. Stopping immunotherapy before the recommended 3-to-5-year course is complete usually means that the immune system will eventually revert to its allergic state, leaving you at risk for anaphylaxis from future spider bites. If you need to stop treatment due to side effects or financial reasons, it is vital to discuss this with your allergist. They can help you understand your remaining risk level and provide guidance on how to manage your allergy without the protection of the extract.
If you miss a scheduled injection of Lycosa Tarantula, you should contact your allergist's office as soon as possible to reschedule. Missing a dose can cause your level of 'venom tolerance' to drop, which makes your next injection potentially more dangerous. Depending on how long it has been since your last shot, your doctor may need to reduce the dose for your next visit and then gradually build it back up. Never try to 'make up' for a missed dose by taking a higher dose or by taking shots closer together than recommended. Consistency is the most important factor for both safety and effectiveness in venom immunotherapy.
There is currently no clinical evidence to suggest that Lycosa Tarantula extracts cause weight gain. Unlike certain medications like corticosteroids or some antidepressants, allergenic extracts do not interfere with the body's metabolism, appetite, or fat storage mechanisms. The proteins in the extract are administered in such small quantities that they have no caloric impact. If you experience unexpected weight gain while undergoing immunotherapy, it is likely due to other factors such as lifestyle changes, other medications, or an underlying medical condition. You should discuss any significant weight changes with your primary care physician to determine the cause.
Lycosa Tarantula can be taken with many common medications, but there are several critical exceptions. The most important interactions are with beta-blockers and ACE inhibitors, which are often used for blood pressure or heart conditions. These drugs can make an allergic reaction much more dangerous and harder to treat. You must provide your allergist with a complete and updated list of every medication you take, including over-the-counter drugs and herbal supplements. In most cases, you can continue taking your regular medications, but your doctor may need to adjust your blood pressure treatment or timing to ensure your safety during immunotherapy.
Lycosa Tarantula is a biological product rather than a simple chemical drug, so the concept of 'generic' versions is slightly different. Biological products are typically referred to as 'biosimilars' or simply different brands of the same standardized extract. While there may be multiple manufacturers of tarantula or spider venom extracts, they are not always interchangeable because the standardization methods (AU vs. PNU) can vary between companies. Always ensure that your immunotherapy is managed by a consistent provider who uses standardized extracts from reputable biological laboratories. Homeopathic versions are widely available from various manufacturers, but these are not substitutes for clinical allergenic extracts.
Other drugs with the same active ingredient (Lycosa Tarantula)
> Warning: Stop taking Lycosa Tarantula and call your doctor immediately or seek emergency care if you experience any of the following:
Long-term use of Lycosa Tarantula in immunotherapy is generally aimed at inducing permanent tolerance. However, prolonged exposure to high doses of any allergen can theoretically lead to:
While Lycosa Tarantula specifically may not have a unique black box warning, all Standardized Insect Venom Allergenic Extracts carry a general warning regarding the risk of severe systemic reactions.
Report any unusual symptoms, even if they seem mild, to your healthcare provider immediately. Early intervention is key to preventing serious complications.
Generally, Lycosa Tarantula does not interfere with the ability to drive. However, if a patient experiences a systemic reaction, dizziness, or is given antihistamines (which cause drowsiness) to treat a local reaction, they should avoid driving until symptoms fully resolve.
Alcohol should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the speed of allergen absorption and potentially trigger or worsen a systemic reaction.
If therapy is discontinued, it must be done under medical guidance. Stopping immunotherapy mid-course simply means the patient remains at risk for their original allergy. There is no 'withdrawal syndrome' associated with Lycosa Tarantula, but the loss of immunological tolerance is a clinical concern.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Lycosa Tarantula.
Mechanism and Management Strategy:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.
Conditions requiring a careful risk-benefit analysis include:
Patients allergic to Lycosa Tarantula may show cross-sensitivity to other members of the Lycosidae family or other arachnids. There is limited evidence of cross-reactivity with Hymenoptera (bees/wasps) venom, but patients with multiple insect allergies should be tested individually for each.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or heart problems, before prescribing Lycosa Tarantula.
Lycosa Tarantula is approved for use in children, primarily those aged 5 and older.
Patients over age 65 are at a higher risk for complications from Lycosa Tarantula therapy.
There are no specific guidelines for dose adjustment in renal impairment. However, clinicians should monitor for signs of systemic inflammation, as patients with chronic kidney disease (CKD) often have a baseline state of immune activation.
No adjustments are required for patients with liver disease, as the metabolism of the extract is not dependent on hepatic enzymes.
> Important: Special populations require individualized medical assessment and a more frequent monitoring schedule to ensure safety.
| Parameter | Value |
|---|---|
| Bioavailability | High (subcutaneous) |
| Protein Binding | N/A (Proteins circulate as free antigens) |
| Half-life | Proteins: Minutes to Hours; Immunological effect: Years |
| Tmax | 1 - 4 hours (for protein absorption) |
| Metabolism | Proteolysis (Protease enzymes) |
| Excretion | Renal (as small peptides/amino acids) |
Lycosa Tarantula is a member of the Standardized Insect Venom Allergenic Extract class. It is related to other venom extracts such as Honey Bee Venom (Apis mellifera) and Yellow Jacket Venom (Vespula species), all of which share the same basic therapeutic goal of desensitization.